Joenja moves closer to broader pediatric APDS label as Pharming Group builds second growth franchise

Pharming Group is moving closer to expanding the commercial reach of Joenja across nearly the full eligible pediatric activated PI3K delta syndrome population in the United States after regulators granted Priority Review to lower doses designed for smaller children. The latest application covers patients aged four years and older weighing between 13 and 27 kilograms, following the recent approval of Joenja for children in the same age range weighing at least 27 kilograms. If the new doses are approved, the United States label would extend to eligible patients aged four years and older weighing at least 13 kilograms, potentially removing one of the remaining restrictions on Pharming Group’s pediatric growth strategy. The FDA has set a January 30, 2027 decision deadline, creating a defined near-term catalyst for a product whose quarterly revenue is already growing around 40% year over year.

The Priority Review is particularly important because Joenja is becoming increasingly central to Pharming Group’s attempt to build a more diversified rare-disease business as revenue from its older RUCONEST franchise faces competitive pressure. Joenja generated $17.9 million in second-quarter revenue, up 40% from the previous year, while RUCONEST revenue declined 10% to $72.3 million. Expanding Joenja into younger and lower-weight children will not transform Pharming Group’s revenue base overnight because activated PI3K delta syndrome is extremely rare, but it could increase penetration within a commercially important United States market while strengthening the broader global leniolisib franchise.

Lower-dose FDA review could close a key remaining gap in Pharming Group’s United States Joenja label

Joenja, also known as leniolisib, is an oral selective PI3K delta inhibitor developed specifically for activated PI3K delta syndrome, commonly abbreviated as APDS. The disorder is caused by pathogenic variants in PIK3CD or PIK3R1 that result in excessive PI3K delta pathway activity and disrupt normal immune-cell development and function.

Patients can experience recurrent respiratory infections, enlarged lymph nodes, autoimmune complications, gastrointestinal disease and progressive organ damage. Diagnosis is often delayed because those manifestations overlap with other primary immunodeficiencies, while untreated or inadequately managed disease can eventually contribute to permanent lung injury and lymphoma. Pharming Group estimates APDS affects approximately one to two people per million worldwide.

The FDA originally approved Joenja for patients aged 12 years and older in 2023. The agency subsequently expanded the label to children aged four to 11 years weighing at least 27 kilograms, approving 40-milligram and 50-milligram twice-daily doses. The newly accepted supplemental New Drug Application is intended to extend treatment to children weighing between 13 and 27 kilograms using lower doses.

That makes the January decision commercially more meaningful than another incremental dosing update. Approval would potentially allow Pharming Group to treat eligible United States APDS patients beginning at age four across a much wider body-weight range, reducing the likelihood that smaller children must wait until they gain sufficient weight before receiving the targeted therapy.

The pediatric opportunity remains numerically small because APDS itself is ultra-rare. Pharming Group had identified 298 diagnosed patients in the United States at the end of June, including 60 children between four and 11 years of age. The company has not disclosed how many of those pediatric patients fall specifically within the 13-to-27-kilogram range, preventing a precise estimate of the incremental revenue opportunity.

For a rare-disease commercial model, however, relatively small numbers of additional patients can still matter. Treatment is chronic, patient identification is highly specialized and successful diagnosis can create long-duration relationships with physicians, treatment centers and families.

Pharming Group has worked through the lower-weight dosing issue that complicated its first pediatric filing

The path toward broader pediatric use has not been straightforward. Pharming Group previously encountered FDA concerns around whether the proposed doses would provide appropriate drug exposure in lower-weight children.

The company subsequently separated its pediatric regulatory strategy by weight. The first resubmission focused on children weighing at least 27 kilograms and led to the approval of the 40-milligram and 50-milligram twice-daily doses. Pharming Group then developed an additional package covering lower doses for children between 13 and 27 kilograms.

The newly accepted application includes clinical pharmacology and scientific assessments intended to demonstrate that smaller patients can achieve appropriate exposure without receiving excessive or inadequate doses. That pharmacological question is now central to the remaining FDA review.

Clinical support comes from an open-label multinational Phase III study in children aged four to 11 years. Over 12 weeks, treatment improved two important biological features of APDS: lymphadenopathy declined and the proportion of naïve B cells increased. Together, those measures provide evidence that leniolisib is influencing the underlying immune dysfunction rather than merely controlling individual symptoms.

The safety profile in the pediatric program has also remained consistent with earlier Joenja experience. In the recently approved group of children weighing at least 27 kilograms, treatment-emergent adverse events were mild to moderate and no drug-related serious adverse events were reported.

Priority Review does not predict approval, but it indicates that the FDA considers the application sufficiently important to evaluate on an accelerated timetable. The January 30, 2027 PDUFA date therefore becomes the key regulatory milestone for completing Pharming Group’s lower-weight United States pediatric strategy.

Joenja revenue growth is becoming increasingly important as RUCONEST faces competitive pressure

The strategic importance of pediatric expansion becomes clearer when viewed alongside Pharming Group’s changing revenue mix. Joenja generated $17.9 million in second-quarter revenue, increasing 40% year over year. First-half revenue reached $32 million, representing growth of 37%. The United States accounted for approximately 86% of second-quarter Joenja sales, underscoring why even a relatively small American label expansion can carry commercial significance.

The number of United States patients receiving paid Joenja therapy reached 132 at the end of June, up 16% from 114 a year earlier. Pharming Group had identified 1,042 diagnosed APDS patients globally across all age groups, providing a patient-finding pipeline that could support further growth as reimbursement and regulatory access expand internationally.

RUCONEST continues to generate considerably more revenue but has faced greater competitive pressure. Second-quarter revenue from the hereditary angioedema therapy declined 10% year over year to $72.3 million, while first-half revenue fell 12% to $130.7 million. Pharming Group attributed the quarterly decline partly to United States market dynamics, specialty pharmacy inventory movements and its withdrawal from non-United States markets.

Those trends make Joenja’s expansion strategically important even before it approaches RUCONEST’s scale. A growing second commercial franchise reduces Pharming Group’s dependence on a single mature product and gives investors a clearer route toward longer-term diversification.

The company has already expanded Joenja geographically. The medicine has approvals across markets including the European Union, Canada, South Korea and Japan, with Japan permitting treatment from age four without the same lower-weight restriction currently present in the United States.

Leniolisib could become substantially more valuable if Pharming expands beyond ultra-rare APDS

The larger commercial opportunity may eventually extend beyond activated PI3K delta syndrome. Pharming Group is evaluating leniolisib in additional primary immunodeficiency disorders involving immune dysregulation, including common variable immunodeficiency. These populations are substantially larger than APDS, meaning successful clinical development could materially increase the addressable market for the molecule.

Two Phase II studies have completed enrollment, with additional clinical readouts expected during the fourth quarter. The programs are evaluating whether abnormal PI3K delta pathway activity identifies broader groups of patients whose immune dysfunction could respond to leniolisib.

That expansion remains investigational. The safety and efficacy of leniolisib have not been established for immune-dysregulation disorders beyond APDS, and positive proof-of-concept evidence would still require additional development before creating a commercial opportunity.

Even so, the strategy gives Joenja a potentially different growth trajectory from a conventional ultra-orphan drug limited permanently to one very small genetically defined population. The pediatric label expansion strengthens the existing franchise while broader immune-dysregulation studies test whether the underlying mechanism can support significantly larger indications.

Pharming Group stock reflects caution despite Joenja growth and multiple regulatory catalysts

Pharming Group’s Nasdaq-listed shares closed the previous session at $10.44, down 3.06%, following a 4.35% decline in the preceding session. The stock remains well below its 52-week high of $21.34, highlighting continued investor caution despite Joenja’s commercial growth and recent pediatric approval.

The pressure reflects a mixed financial picture. Pharming Group reported total second-quarter revenue of $90.2 million, down 3% year over year, while operating profit fell to $1.3 million from $10.8 million. The company also reduced full-year revenue guidance to $375 million to $395 million, although it simultaneously lowered its expected operating expenses.

Cash, restricted cash and marketable securities totaled $159.5 million at the end of June, giving Pharming Group resources to support commercialization and pipeline development. The company remains profitable at the quarterly operating level, but its growth narrative increasingly depends on Joenja offsetting pressure within RUCONEST and on pipeline investments generating additional products or indications.

Analyst sentiment remains more optimistic than recent share-price performance. Canaccord Genuity recently maintained a Buy rating and $38 price target following positive leniolisib data, while Oppenheimer retained an Outperform rating with a $39 target after modestly reducing its estimate. Those targets represent analyst opinions rather than guarantees, but they indicate that parts of Wall Street continue assigning substantial value to Joenja and Pharming Group’s broader rare-disease pipeline.

The FDA Priority Review does not by itself materially change Pharming Group’s near-term revenue outlook. The number of lower-weight children with diagnosed APDS is simply too small for the label expansion alone to transform the business.

Its strategic value is broader. Approval would close an important pediatric treatment gap, expand the available United States patient pool, remove a lingering regulatory issue and strengthen Joenja as the company’s fastest-growing commercial franchise. Combined with international launches and potential development beyond APDS, that progress could gradually shift Pharming Group away from dependence on RUCONEST and toward a more diversified rare-disease growth model.

Key takeaways from Pharming Group’s Joenja pediatric FDA review

• The FDA granted Priority Review for lower-dose Joenja in children with APDS aged four and older who weigh 13–27 kilograms.
• A regulatory decision is expected by January 30, 2027, creating a defined near-term catalyst for Pharming Group.
• Approval would extend Joenja treatment across a broader pediatric weight range in the United States.
• The filing follows earlier FDA concerns over drug exposure in lower-weight children, which Pharming Group addressed with additional pharmacology data.
• Pediatric Phase III results showed improvement in lymphadenopathy and naïve B-cell levels, supporting Joenja’s disease-targeted mechanism.
• Joenja generated $17.9 million in second-quarter revenue, rising 40% year over year as patient adoption continued to expand.
• RUCONEST revenue declined 10% during the quarter, making Joenja increasingly important to Pharming Group’s future growth mix.
• The United States remains Joenja’s largest market, accounting for about 86% of second-quarter product revenue.
• Pharming Group is also evaluating leniolisib beyond APDS, creating potential longer-term opportunities in broader immune-dysregulation disorders.